Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells

ABSTRACT The “shock and kill” model of human immunodeficiency virus type 1 (HIV-1) eradication involves the induction of transcription of HIV-1 genes in latently infected CD4+ T cells, followed by the elimination of these infected CD4+ T cells by CD8+ T cells or other effector cells. CD8+ T cells may also be needed to control the spread of new infection if residual infected cells are present at the time combination antiretroviral therapy (cART) is discontinued. In order to determine the time frame needed for CD8+ T cells to effectively prevent the spread of HIV-1 infection, we examined the kinetics of HIV transcription and virus release in latently infected cells reactivated ex vivo. Isolated resting, primary CD4+ T cells from HIV-positive (HIV+) subjects on suppressive regimens were found to upregulate cell-associated HIV-1 mRNA within 1 h of stimulation and produce extracellular virus as early as 6 h poststimulation. In spite of the rapid kinetics of virus production, we show that CD8+ T cells from 2 out of 4 viremic controllers were capable of effectively eliminating reactivated autologous CD4+ cells that upregulate cell-associated HIV-1 mRNA. The results have implications for devising strategies to prevent rebound viremia due to reactivation of rare latently infected cells that persist after potentially curative therapy. IMPORTANCE A prominent HIV-1 cure strategy termed “shock and kill” involves the induction of HIV-1 transcription in latently infected CD4+ T cells with the goal of elimination of these cells by either the cytotoxic T lymphocyte response or other immune cell subsets. However, the cytotoxic T cell response may also be required after curative treatment if residual latently infected cells remain. The kinetics of HIV-1 reactivation indicate rapid upregulation of cell-associated HIV-1 mRNA and a 5-h window between transcription and virus release. Thus, HIV-specific CD8+ T cell responses likely have a very short time frame to eliminate residual latently infected CD4+ T cells that become reactivated after discontinuation of antiretroviral therapy following potentially curative treatment strategies.

[1]  S. Lam,et al.  Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. , 2015, The Journal of infectious diseases.

[2]  Daniel I. S. Rosenbloom,et al.  Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. , 2015, The Journal of clinical investigation.

[3]  N. Klein,et al.  Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. , 2015, The Pediatric infectious disease journal.

[4]  Katherine Luzuriaga,et al.  Viremic relapse after HIV-1 remission in a perinatally infected child. , 2015, The New England journal of medicine.

[5]  Emily B Hanhauser,et al.  Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation , 2014, Annals of Internal Medicine.

[6]  D. Irvine,et al.  Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes , 2014, PLoS pathogens.

[7]  R. Siliciano,et al.  Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo , 2014, Nature Medicine.

[8]  D. Margolis,et al.  Emerging strategies to deplete the HIV reservoir , 2014, Current opinion in infectious diseases.

[9]  R. Siliciano,et al.  HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4+ T Cell Depletion in Humanized BLT Mice , 2014, Journal of Virology.

[10]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[11]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[12]  R. Siliciano,et al.  HIV-1 eradication strategies: design and assessment , 2013, Current opinion in HIV and AIDS.

[13]  R. Siliciano,et al.  Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells , 2013, Retrovirology.

[14]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[15]  J. Blankson,et al.  Inhibitory Potential of Subpopulations of CD8+ T Cells in HIV-1-Infected Elite Suppressors , 2012, Journal of Virology.

[16]  F. Pereyra,et al.  Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control , 2010, PLoS pathogens.

[17]  C. Van Lint,et al.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies , 2009, Retrovirology.

[18]  C. Hallahan,et al.  Defective Human Immunodeficiency Virus-Specific CD8+ T-Cell Polyfunctionality, Proliferation, and Cytotoxicity Are Not Restored by Antiretroviral Therapy , 2009, Journal of Virology.

[19]  C. Hallahan,et al.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. , 2008, Immunity.

[20]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[21]  Asier Sáez-Cirión,et al.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.

[22]  R. Siliciano,et al.  Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors , 2006, Journal of Virology.

[23]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[24]  Jared E. Toettcher,et al.  Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.

[25]  Alan S Perelson,et al.  Estimates of Intracellular Delay and Average Drug Efficacy from Viral Load Data of HIV-Infected Individuals under Antiretroviral Therapy , 2004, Antiviral therapy.

[26]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[27]  C. Hallahan,et al.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.

[28]  H. Akari,et al.  Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Cytolytic Activity and Cytokine Production , 2002, Journal of Virology.

[29]  B. Walker,et al.  Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes , 2002, Journal of Virology.

[30]  R. Koup,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific CD8+ T Cells in Peripheral Blood after Initiation of Highly Active Antiretroviral Therapy , 2001, Journal of Virology.

[31]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[32]  D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[33]  G. Nolan,et al.  Host Control of HIV-1 Parasitism in T Cells by the Nuclear Factor of Activated T Cells , 1998, Cell.

[34]  B. Walker,et al.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes , 1998, Nature.

[35]  M. Mathews,et al.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.

[36]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[37]  F. Lemonnier,et al.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein , 1996, Nature Medicine.

[38]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[39]  D. Baltimore,et al.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression , 1989, Journal of virology.

[40]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[41]  A. Fauci,et al.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. , 1986, Science.

[42]  Larry W. Moreland,et al.  Nuclear factor of activated T-cells , 2004 .